{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,18]],"date-time":"2025-10-18T10:51:23Z","timestamp":1760784683483,"version":"3.37.3"},"reference-count":6,"publisher":"The Endocrine Society","issue":"10","license":[{"start":{"date-parts":[[2019,8,7]],"date-time":"2019-08-07T00:00:00Z","timestamp":1565136000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000062","name":"NIDDK","doi-asserted-by":"publisher","award":["T32DK007028"],"award-info":[{"award-number":["T32DK007028"]}],"id":[{"id":"10.13039\/100000062","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2019,10,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Non\u2013small cell lung cancer with pituitary metastasis (NSCLC-PM) is a devastating disease; however, treatment is being revolutionized by a novel therapy targeting highly specific tumor signals, such as the mutation of epidermal growth factor receptors (EGFRs). Long-term management of hormonal defects in this population has become a unique neuroendocrine clinical challenge. We report the case of a 73-year-old female nonsmoker who was diagnosed with stage IV non\u2013small cell lung cancer. The initial staging evaluation revealed a 7 \u00d7 11 \u00d7 21-mm sellar lesion abutting the optic chiasm and causing clinical hypopituitarism. The patient received three cycles of chemotherapy with carboplatin and pemetrexed, which was discontinued because of major cumulative side effects of myelosuppression and kidney disease. Eight months later, scans demonstrated evidence of disease progression. A repeated lung nodule biopsy revealed an EGFR exon 19 deletion mutation. EGFR-targeted therapy with osimertinib 80 mg daily was initiated. A complete resolution of the pituitary lesion was evident on a follow-up pituitary MRI 5 weeks later and was sustained 1 year after. However, the panhypopituitarism persisted. This is an illustrative case of NSCLC-PM with EGFR exon 19 deletion mutation, wherein osimertinib, a third-generation EGFR\u2012tyrosine kinase inhibitor, eradicated the sellar metastasis and prevented the need for radiotherapy. However, the neuroendocrine deficits persisted despite anatomic improvement.<\/jats:p>","DOI":"10.1210\/js.2019-00217","type":"journal-article","created":{"date-parts":[[2019,8,13]],"date-time":"2019-08-13T12:35:15Z","timestamp":1565699715000},"page":"1887-1891","source":"Crossref","is-referenced-by-count":4,"title":["Complete Resolution of Sellar Metastasis in a Patient With NSCLC Treated With Osimertinib"],"prefix":"10.1210","volume":"3","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5081-4809","authenticated-orcid":false,"given":"WuQiang","family":"Fan","sequence":"first","affiliation":[{"name":"Neuroendocrine and Pituitary Tumor Clinical Center, Department of Medicine, Massachusetts General Hospital, Boston, Massachusetts"},{"name":"Diabetes Center, Department of Medicine, Massachusetts General Hospital, Boston, Massachusetts"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jason","family":"Sloane","sequence":"additional","affiliation":[{"name":"Neuroendocrine and Pituitary Tumor Clinical Center, Department of Medicine, Massachusetts General Hospital, Boston, Massachusetts"},{"name":"Diabetes Center, Department of Medicine, Massachusetts General Hospital, Boston, Massachusetts"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lisa B","family":"Nachtigall","sequence":"additional","affiliation":[{"name":"Neuroendocrine and Pituitary Tumor Clinical Center, Department of Medicine, Massachusetts General Hospital, Boston, Massachusetts"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"80","published-online":{"date-parts":[[2019,8,7]]},"reference":[{"issue":"8","key":"2019100117015147000_bib1","doi-asserted-by":"crossref","first-page":"3379","DOI":"10.1210\/jc.2019-00012","article-title":"Pituitary metastases: a nationwide study on current characteristics with special reference to breast cancer","volume":"104","author":"Schill","year":"2019","journal-title":"J Clin Endocrinol Metab"},{"issue":"10","key":"2019100117015147000_bib2","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1530\/EC-18-0338","article-title":"Pituitary metastasis: a rare condition","volume":"7","author":"Javanbakht","year":"2018","journal-title":"Endocr Connect"},{"issue":"1","key":"2019100117015147000_bib3","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1007\/s11102-014-0552-2","article-title":"Metastatic involvement of the pituitary gland: a systematic review with pooled individual patient data analysis","volume":"18","author":"He","year":"2015","journal-title":"Pituitary"},{"issue":"5","key":"2019100117015147000_bib4","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1007\/s11102-018-0899-x","article-title":"Twelve cases of pituitary metastasis: a case series and review of the literature","volume":"21","author":"Castle-Kirszbaum","year":"2018","journal-title":"Pituitary"},{"issue":"2","key":"2019100117015147000_bib5","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1056\/NEJMoa1713137","article-title":"Osimertinib in untreated EGFR-mutated advanced non\u2012small-cell lung cancer","volume":"378","author":"Soria","year":"2018","journal-title":"N Engl J Med"},{"issue":"7","key":"2019100117015147000_bib6","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1056\/NEJMoa1612674","article-title":"Osimertinib or platinum-pemetrexed in EGFR T790M\u2012positive lung cancer","volume":"376","author":"Mok","year":"2017","journal-title":"N Engl J Med"}],"container-title":["Journal of the Endocrine Society"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/jes\/advance-article-pdf\/doi\/10.1210\/js.2019-00217\/29104940\/js.2019-00217.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/jes\/article-pdf\/3\/10\/1887\/30094156\/js.2019-00217.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,10,1]],"date-time":"2019-10-01T18:36:52Z","timestamp":1569955012000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jes\/article\/3\/10\/1887\/5544503"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,8,7]]},"references-count":6,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2019,10,1]]}},"URL":"https:\/\/doi.org\/10.1210\/js.2019-00217","relation":{},"ISSN":["2472-1972"],"issn-type":[{"type":"electronic","value":"2472-1972"}],"subject":[],"published-other":{"date-parts":[[2019,10]]},"published":{"date-parts":[[2019,8,7]]}}}